Compare ALLO & NQP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALLO | NQP |
|---|---|---|
| Founded | 2017 | 1990 |
| Country | United States | United States |
| Employees | 152 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 738.4M | 449.2M |
| IPO Year | 2018 | N/A |
| Metric | ALLO | NQP |
|---|---|---|
| Price | $2.02 | $12.03 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 15 | 0 |
| Target Price | ★ $8.35 | N/A |
| AVG Volume (30 Days) | ★ 8.0M | 141.0K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.21% |
| EPS Growth | ★ 34.09 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $142,416.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.99 | $10.72 |
| 52 Week High | $4.46 | $12.22 |
| Indicator | ALLO | NQP |
|---|---|---|
| Relative Strength Index (RSI) | 38.70 | 55.07 |
| Support Level | $1.85 | $11.98 |
| Resistance Level | $2.71 | $12.17 |
| Average True Range (ATR) | 0.14 | 0.08 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 8.33 | 65.71 |
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
Nuveen Pennsylvania Quality Municipal Income Fund is a closed-end fixed income mutual fund. The fund's investment objectives are (i) to provide current income exempt from regular federal income tax, the federal alternative minimum tax applicable to individuals and California income tax and (ii) to enhance portfolio value relative to the municipal bond market by investing in tax- exempt municipal securities that the Fund's investment adviser and/or the Fund's sub-adviser, believes are underrated or undervalued or that represent municipal market sectors that are undervalued. The fund prominenty invests in tax-exempt municipal bonds from Pennsylvania that are investment grade.